EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine

Richard B Lipton, Pranav Gandhi iD, Andreas R Gantenbein, Brett Dabruzzo, Karen Carr, Jonathan Stokes, Molly Duan, Rashmi B Halker Singh iD, Hsiangkuo Yuan, Dawn C Buse

Headache: The Journal of Head and Face Pain · 2026-11 · 66 (10) · 2264-2276

DOI: 10.1111/head.70188 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 22.09.2026. Verfasst von Richard B Lipton und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Piperidines, Activities of Daily Living. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evaluate early functional improvements with the preventive migraine treatment atogepant using Activity Impairment in Migraine–Diary (AIM‐D) individual and activity limitation items, and complete improvement in AIM‐D Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores assessed weekly during the first 4 weeks of three phase 3 trials.

Background

Patient‐reported functional outcomes are critical for assessing response to preventive migraine treatments, yet analyses of treatment effects on function at early timepoints are limited.

Methods

Post hoc analyses assessed AIM‐D data in three multicenter, placebo‐controlled, double‐blind, parallel‐group, 12‐week, randomized clinical trials in participants who received once‐daily atogepant 60 mg or placebo: ADVANCE (episodic migraine [EM], 4–14 monthly migraine days [MMDs]; United States trial, December 14, 2018–June 19, 2020), ELEVATE (EM with prior failure to two to four classes of oral preventive migraine treatments; international trial, March 5, 2021–August 4, 2022), and PROGRESS (chronic migraine [CM]; ≥15 monthly headache days, including ≥8 MMDs; international trial, March 11, 2019–January 20, 2022). A separate activity limitation item was included in the daily eDiary to assess limitation of activity over the past 24 h. The percent change from baseline in each AIM‐D item score and the activity limitation item score, and the proportions of participants achieving complete improvement (i.e., scores of zero) in AIM‐D PDA or PI domain scores, were evaluated at weeks 1 through 4. A mixed model for repeated measures analysis compared least squares mean change from baseline in individual AIM‐D items and activity limitation. A generalized linear mixed model compared the relative odds of achieving complete improvement.

Results

In ADVANCE, ELEVATE, and PROGRESS, participants treated with atogepant versus placebo generally had a greater reduction in the individual AIM‐D item scores at weeks 1 (ADVANCE, p:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersPiperidinesActivities of Daily LivingHumansDouble-Blind MethodFemaleAdultMaleTreatment OutcomeMiddle AgedPatient Reported Outcome MeasuresPyridinesPyrrolesSpiro Compounds

Stichwörter der Autor:innen

atogepantcalcitonin gene–related peptidemigraine disorderspatient‐reported functional outcome measures

Substanzen

atogepantPiperidinesPyridinesPyrrolesSpiro Compounds

Autor:innen und Institutionen

  • The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • AbbVie, North Chicago, Illinois, USA.
  • Department of Neurology, Neurorehabilitation and Pain, ZURZACH Care, Bad Zurzach, Switzerland.
  • Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA.
  • Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Pranav Gandhi, Rashmi B Halker Singh

Förderung

  • AbbVie

Zitieren

APA

Lipton, R. B., Gandhi, P., Gantenbein, A. R., Dabruzzo, B., Carr, K., Stokes, J., Duan, M., Halker Singh, R. B., Yuan, H., & Buse, D. C. (2026). Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine. Headache: The Journal of Head and Face Pain, 66(10), 2264-2276. https://doi.org/10.1111/head.70188

Vancouver

Lipton RB, Gandhi P, Gantenbein AR, Dabruzzo B, Carr K, Stokes J, et al. Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine. Headache: The Journal of Head and Face Pain. 2026;66(10):2264-2276. doi:10.1111/head.70188

BibTeX
@article{Lipton2026,
  author = {Lipton, Richard B and Gandhi, Pranav and Gantenbein, Andreas R and Dabruzzo, Brett and Carr, Karen and Stokes, Jonathan and Duan, Molly and Halker Singh, Rashmi B and Yuan, Hsiangkuo and Buse, Dawn C},
  title = {Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {10},
  pages = {2264--2276},
  doi = {10.1111/head.70188}
}
Kostenlos starten →